Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid–protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins
Sohvi Hörkkö, … , Wulf Palinski, Joseph L. Witztum
Sohvi Hörkkö, … , Wulf Palinski, Joseph L. Witztum
Published January 1, 1999
Citation Information: J Clin Invest. 1999;103(1):117-128. https://doi.org/10.1172/JCI4533.
View: Text | PDF
Article Article has an altmetric score of 9

Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid–protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins

  • Text
  • PDF
Abstract

We recently cloned monoclonal IgM autoantibodies which bind to epitopes of oxidized low-density lipoprotein (OxLDL) from apoE-deficient mice (EO– autoantibodies). We now demonstrate that those EO– autoantibodies that were originally selected for binding to copper-oxidized low-density lipoproteins (CuOx-LDL), also bound both to the oxidized protein and to the oxidized lipid moieties of CuOx-LDL. The same EO– autoantibodies showed specific binding to products of oxidized 1-palmitoyl-2-arachidonoyl-phosphatidylcholine (OxPAPC) and to the specific oxidized phospholipid, 1-palmitoyl-2-(5-oxovaleroyl)-phosphatidyl-choline (POVPC), whereas oxidation of fatty acids (linoleic or arachidonic acid) or cholesteryl esters (cholesteryl-oleate or cholesteryl-linoleate) did not yield any binding activity. Those EO– autoantibodies that bound to oxidized phospholipids (e.g., EO6) inhibited the binding and degradation of CuOx-LDL by mouse peritoneal macrophages up to 91%, whereas other IgM EO– autoantibodies, selected for binding to malondialdehyde (MDA)-LDL, had no influence on binding of either CuOx-LDL or MDA-LDL by macrophages. F(ab′)2 fragments of EO6 were equally effective as the intact EO6 in preventing the binding of CuOx-LDL by macrophages. The molar ratios of IgM to LDL needed to maximally inhibit the binding varied from ∼8 to 25 with different CuOx-LDL preparations. Finally, a POVPC–bovine serum albumin (BSA) adduct also inhibited CuOx-LDL uptake by macrophages. These data suggest that oxidized phospholipid epitopes, present either as lipids or as lipid-protein adducts, represent one class of ligands involved in the recognition of OxLDL by macrophages, and that apoE-deficient mice have IgM autoantibodies that can bind to these neoepitopes and inhibit OxLDL uptake.

Authors

Sohvi Hörkkö, David A. Bird, Elizabeth Miller, Hiroyuki Itabe, Norbert Leitinger, Ganesamoorthy Subbanagounder, Judith A. Berliner, Peter Friedman, Edward A. Dennis, Linda K. Curtiss, Wulf Palinski, Joseph L. Witztum

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1997 1995 Total
Citations: 7 3 9 21 19 15 20 8 18 10 21 20 30 15 16 14 25 12 19 19 24 20 18 14 25 11 1 2 436
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2008 (25)

Title and authors Publication Year
IL-33 reduces the development of atherosclerosis
AM Miller, D Xu, DL Asquith, L Denby, Y Li, N Sattar, AH Baker, IB McInnes, FY Liew
Journal of Experimental Medicine 2008
Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE and APOECD40L mice
ML Smook, M Leeuwen, P Heeringa, JG Damoiseaux, R Theunissen, MJ Daemen, E Lutgens, JW Tervaert
Clinical & Experimental Immunology 2008
Oxidation-specific epitopes are important targets of innate immunity
MY Chou, K Hartvigsen, LF Hansen, L Fogelstrand, PX Shaw, A Boullier, CJ Binder, JL Witztum
Journal of Internal Medicine 2008
Genetic imprinting of autoantibody repertoires in systemic lupus erythematosus patients
GJ Silverman, R Srikrishnan, K Germar, CS Goodyear, KA Andrews, EM Ginzler, BP Tsao
Clinical & Experimental Immunology 2008
Plasma Interleukin-5 Levels Are Related to Antibodies Binding to Oxidized Low-Density Lipoprotein and to Decreased Subclinical Atherosclerosis
M Sämpi, O Ukkola, M Päivänsalo, YA Kesäniemi, CJ Binder, S Hörkkö
Journal of the American College of Cardiology 2008
Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes
KC Briley-Saebo, PX Shaw, WJ Mulder, SH Choi, E Vucic, JG Aguinaldo, JL Witztum, V Fuster, S Tsimikas, ZA Fayad
Circulation 2008
Lipid peroxidation and decomposition — Conflicting roles in plaque vulnerability and stability
S Parthasarathy, D Litvinov, K Selvarajan, M Garelnabi
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2008
Lipids in Health and Disease
PJ Quinn, X Wang
Lipids in Health and Disease 2008
Lipids in Health and Disease
PJ Quinn, X Wang
Lipids in Health and Disease 2008
Lipids in Health and Disease
PJ Quinn, X Wang
Lipids in Health and Disease 2008
Reviews of Physiology Biochemistry and Pharmacology
SG Amara, E Bamberg, B Fleischmann, T Gudermann, SC Hebert, R Jahn, WJ Lederer, R Lill, A Miyajima, S Offermanns, R Zechner
Reviews of Physiology Biochemistry and Pharmacology 2008
Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)
DM Stafforini
Cardiovascular Drugs and Therapy 2008
Autoimmunity in atherosclerosis: a protective response losing control?
J Nilsson, GK Hansson
Journal of Internal Medicine 2008
The aldo-keto reductase superfamily and its role in drug metabolism and detoxification
OA Barski, SM Tipparaju, A Bhatnagar
Drug Metabolism Reviews 2008
Accelerated atherosclerosis in ApoE deficient lupus mouse models
Z Ma, A Choudhury, SA Kang, M Monestier, PL Cohen, RA Eisenberg
Clinical Immunology 2008
Autoantibody Response to Chromatographic Fractions from Oxidized LDL in Unstable Angina Patients and Healthy Controls
DF Ketelhuth, GC Tonini, MD Carvalho, RF Ramos, P Boschcov, M Gidlund
Scandinavian Journal of Immunology 2008
Inverse relation between levels of anti-oxidized-LDL antibodies and eicosapentanoic acid (EPA)
L Garrido-Sánchez, E García-Fuentes, G Rojo-Martínez, F Cardona, F Soriguer, FJ Tinahones
British Journal of Nutrition 2008
Circulating oxidized lipoproteins and cardiovascular risk
H Itabe
Current Cardiovascular Risk Reports 2008
Oxidation of LDL and its clinical implication
E Matsuura, GR Hughes, MA Khamashta
Autoimmunity Reviews 2008
Anti-oxidized low-density lipoprotein antibody levels are associated with the development of type 2 diabetes mellitus
L Garrido-Sánchez, F Cardona, E García-Fuentes, G Rojo-Martínez, JM Gómez-Zumaquero, MJ Picón, F Soriguer, FJ Tinahones
European Journal of Clinical Investigation 2008
Oxidized Low-Density Lipoprotein Is Not Equal to Oxidative Stress
LJ van Tits, AF Stalenhoef
The American Journal of Cardiology 2008
Generation and Identification of Natural Monoclonal Antibodies Against Low-Density Lipoprotein
X Feng, R Xu, Y Gao, Z He, C Li, H Wang
Hybridoma 2008
In Vivo Markers of Oxidative Stress and Therapeutic Interventions
S Tsimikas
The American Journal of Cardiology 2008
The role of innate immunity in atherogenesis: Fig. 1
K Hartvigsen, MY Chou, LF Hansen, PX Shaw, S Tsimikas, CJ Binder, JL Witztum
Journal of lipid research 2008
Interaction of Cytochrome c with 1-Palmitoyl-2-azelaoyl- sn -glycero-3-phosphocholine: Evidence for Acyl Chain Reversal
JP Mattila, K Sabatini, PK Kinnunen
Langmuir 2008

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 12 patents
148 readers on Mendeley
1 readers on CiteULike
See more details